Drug Trial Radar · NCT05421429
KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia
Last checked: Nov 19, 2026Latest source record: Dec 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jul 7, 2022
Primary completion
Jan 17, 2024
Study completion Jan 17, 2024
Sponsor
- Lead sponsor
- Suzhou Alphamab Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous doses of KN057 in subjects with hemophilia A or B, with or without inhibitors to Factor VIII (FVIII) or Factor IX (FIX). 24 adult participants 18 to 70 years of age with moderately severe to severe hemophilia A or hemophilia B (defined as FVIII or FIX activity ≤2%, respectively) with or without inhibitors (including 18 HA/HB patients without inhibitors and 6 HA/HB patients with inhibitors) are expected to be enrolled in this study during which they will receive prophylaxis treatment (defined as treatment by SC injection once weekly of KN057).
Conditions
- Hemophilia
Interventions
KN057 doseⅠBiological
KN057 subcutaneous (SC) injection
KN057 dose ⅡBiological
KN057 SC injection
KN057 dose ⅢBiological
KN057 SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of treatment emergent adverse events(TEAEs)Time frame: Day 1 up to Day 85
- Withdrawals due to TEAEsTime frame: Day 1 up to Day 85
- Number of Participants With Abnormal Laboratory Findings-HematologyTime frame: Day 1 up to Day 85
- Number of Participants With Abnormal Laboratory Findings-UrinalysisTime frame: Day 1 up to Day 85
- Number of Participants With Abnormal Laboratory Findings-Blood biochemistryTime frame: Day 1 up to Day 85
- Number of Participants With Abnormal Laboratory Findings-Coagulation testsTime frame: Day 1 up to Day 85
- Number of Participants With Clinically Significant Changes in Vital Signs DataTime frame: Day 1 up to Day 85
- Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG)Time frame: Day 1 up to Day 85
- Number of Participants With Clinically Significant Changes in Physical Examination FindingsTime frame: Day 1 up to Day 85
- Number of Participants With Injection Site ReactionsTime frame: Day 1 up to Day 85
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
stitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.